LFMD vs QTRX
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
LFMD exhibits severe financial deterioration, highlighted by a weak Piotroski F-Score of 2/9 and a catastrophic Q/Q revenue decline of 88.98%. While the company maintains a low debt-to-equity ratio, the combination of negative operating margins, a deeply negative ROE (-131.16%), and a 0/4 earnings beat record over the last four quarters indicates a business in crisis. Despite a high analyst target price of $9.88, the fundamental data and technical trend (0/100) suggest a value trap scenario.
QTRX exhibits severe financial distress as evidenced by a Piotroski F-Score of 1/9, indicating critical weakness in operational efficiency and financial health. While the company maintains strong top-line revenue growth (24.7% YoY) and a healthy current ratio (2.84), these are overshadowed by a devastating profit margin of -77.14% and a consistent track record of missing earnings estimates. The stock is in a clear long-term downtrend, having lost over 94% of its value over five years, and currently trades at a significant discount to book value (P/B 0.55), suggesting a 'value trap' scenario.
Compare Another Pair
Related Comparisons
LFMD vs QTRX: Head-to-Head Comparison
This page compares LifeMD, Inc. (LFMD) and Quanterix Corporation (QTRX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.